These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31589978)

  • 1. How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?
    Vermeire S; Dreesen E; Papamichael K; Dubinsky MC
    Clin Gastroenterol Hepatol; 2020 May; 18(6):1291-1299. PubMed ID: 31589978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
    Hoseyni H; Xu Y; Zhou H
    J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases.
    Bourchany A; Gilletta De Saint-Joseph C; Breton A; Barreau F; Mas E
    Curr Opin Pharmacol; 2020 Oct; 54():51-58. PubMed ID: 32947075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
    Mitrev N; Leong RW
    Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
    Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.
    Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS
    Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
    Papamichael K; Cheifetz AS
    Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases.
    Kantasiripitak W; Wang Z; Spriet I; Ferrante M; Dreesen E
    Expert Rev Clin Pharmacol; 2021 Dec; 14(12):1455-1466. PubMed ID: 35034509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
    Alsoud D; Vermeire S; Verstockt B
    Curr Opin Pharmacol; 2020 Dec; 55():17-30. PubMed ID: 33039940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease.
    Franca R; Curci D; Lucafò M; Decorti G; Stocco G
    Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):527-539. PubMed ID: 31177858
    [No Abstract]   [Full Text] [Related]  

  • 13. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.
    Vande Casteele N; Herfarth H; Katz J; Falck-Ytter Y; Singh S
    Gastroenterology; 2017 Sep; 153(3):835-857.e6. PubMed ID: 28774547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?
    Strik AS; Berends SE; Löwenberg M
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):885-891. PubMed ID: 31305158
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic drug monitoring for biological medications in inflammatory bowel disease.
    Cogan RC; El-Matary BW; El-Matary WM
    Saudi J Gastroenterol; 2022; 28(5):322-331. PubMed ID: 35343213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
    Papamichael K; Cheifetz AS
    Curr Opin Gastroenterol; 2019 Jul; 35(4):302-310. PubMed ID: 30973355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring.
    Desai DC; Dherai AJ; Strik A; Mould DR
    J Clin Pharmacol; 2023 Apr; 63(4):480-489. PubMed ID: 36458468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease.
    Sheasgreen C; Nguyen GC
    Curr Gastroenterol Rep; 2017 May; 19(5):19. PubMed ID: 28397129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
    Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
    Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.
    Strik AS; Bots SJ; D'Haens G; Löwenberg M
    Expert Rev Clin Pharmacol; 2016; 9(3):429-39. PubMed ID: 26681400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.